688062 迈威生物-U
已收盘 07-10 15:00:02
资讯
新帖
简况
每周股票复盘：迈威生物（688062）9MW5211注射液获批T1DM临床试验
证券之星 · 02:49
每周股票复盘：迈威生物（688062）9MW5211注射液获批T1DM临床试验
迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准
美股速递 · 07-07
迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准
迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准
智通财经 · 07-07
迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准
迈威生物：9MW5211注射液获国家药监局批准开展1型糖尿病临床试验
格隆汇 · 07-07
迈威生物：9MW5211注射液获国家药监局批准开展1型糖尿病临床试验
迈威生物（688062）2607万股限售股将于7月3日解禁，占总股本5.84%
证券之星 · 07-03
迈威生物（688062）2607万股限售股将于7月3日解禁，占总股本5.84%
迈威生物（688062）披露首次公开发行部分限售股上市流通公告，6月25日股价上涨0.14%
证券之星 · 06-25
迈威生物（688062）披露首次公开发行部分限售股上市流通公告，6月25日股价上涨0.14%
迈威生物-U获国家药监局批准开展6MW5311注射液临床试验申请
投资观察 · 06-23
迈威生物-U获国家药监局批准开展6MW5311注射液临床试验申请
迈威生物(688062.SH)：注射用6MW5311临床试验申请获国家药监局批准
智通财经 · 06-23
迈威生物(688062.SH)：注射用6MW5311临床试验申请获国家药监局批准
迈威生物（688062）披露召开2025年度暨2026年第一季度业绩说明会公告，6月22日股价下跌1.24%
证券之星 · 06-22
迈威生物（688062）披露召开2025年度暨2026年第一季度业绩说明会公告，6月22日股价下跌1.24%
每周股票复盘：迈威生物（688062）9MW2821临床数据亮相ESMO Gynae
证券之星 · 06-20
每周股票复盘：迈威生物（688062）9MW2821临床数据亮相ESMO Gynae
迈威生物宣布胡慧国将卸任执行董事
投资观察 · 06-19
迈威生物宣布胡慧国将卸任执行董事
迈威生物第三届董事会选举唐春山、刘大涛、吴海、华军为执行董事 决议现已生效
美股速递 · 06-18
迈威生物第三届董事会选举唐春山、刘大涛、吴海、华军为执行董事 决议现已生效
迈威生物-U（688062）6MW5311临床试验申请获国家药监局受理审评
美股速递 · 06-12
迈威生物-U（688062）6MW5311临床试验申请获国家药监局受理审评
迈威生物-U获美国FDA批准开展临床试验
美股速递 · 06-12
迈威生物-U获美国FDA批准开展临床试验
迈威生物(688062.SH)：注射用6MW5311临床试验申请获得FDA许可
智通财经 · 06-12
迈威生物(688062.SH)：注射用6MW5311临床试验申请获得FDA许可
每周股票复盘：迈威生物（688062）召开两次临时股东会
证券之星 · 06-07
每周股票复盘：迈威生物（688062）召开两次临时股东会
迈威生物-U 9MW5211注射液临床试验申请获国家药监局批准
投资观察 · 06-04
迈威生物-U 9MW5211注射液临床试验申请获国家药监局批准
迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准
美股速递 · 06-04
迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准
迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准
智通财经 · 06-04
迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准
从ASCO数据到迈卫健扩围：迈威生物创新与商业化并进
格隆汇 · 06-03
从ASCO数据到迈卫健扩围：迈威生物创新与商业化并进
加载更多
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":31.87,"timestamp":1783666802000,"preClose":31.05,"halted":0,"volume":13651087,"delay":0,"changeRate":0.0264,"floatShares":229999999,"shares":447000000,"eps":-2.0584,"marketStatus":"已收盘","change":0.82,"latestTime":"07-10 15:00:02","open":30.66,"high":33.5,"low":30.21,"amount":437000000,"amplitude":0.106,"askPrice":31.89,"askSize":23,"bidPrice":31.87,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-2.0584,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783906200000},"marketStatusCode":5,"adr":0,"adjPreClose":31.05,"symbolType":"stock_kcb","openAndCloseTimeList":[[1783647000000,1783654200000],[1783659600000,1783666800000]],"highLimit":34.16,"lowLimit":27.95,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446730200,"isCdr":false,"pbRate":133.29,"roa":"--","roe":"--","epsLYR":-2.43,"committee":-0.052632,"marketValue":14237000000,"turnoverRate":0.0593,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-07-13。","afterMarket":{"amount":127480,"volume":4000,"close":31.87,"buyVolume":0,"sellVolume":84,"time":1783668837746,"indexStatus":"已收盘 07-10 15:30:00","preClose":31.05},"hkstockBrief":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":23.5,"timestamp":1783670914921,"preClose":22.5,"halted":0,"volume":316200,"delay":0,"premium":"-36.22"},"floatMarketCap":7338000000},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"2650115423","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获批T1DM临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2650115423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650115423?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:49","pubTimestamp":1783795748,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，迈威生物报收于31.87元，较上周的32.06元下跌0.59%。本周关注点公司公告汇总：9MW5211注射液用于1型糖尿病适应症的临床试验申请获国家药监局批准公司公告汇总：该药品此前已获批用于炎症性肠病和多发性硬化适应症的临床试验公司公告汇总：9MW5211注射液针对多种自身免疫性疾病核心病理机制，具高度特异性公司公告汇总迈威生物自愿披露关于9MW5211注射液临床试验申请获得国家药品监督管理局批准的公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688062","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198547368","title":"迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1198547368","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198547368?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:16","pubTimestamp":1783430197,"startTime":"0","endTime":"0","summary":"迈威生物-U (688062) 宣布，其研发的9MW5211注射液临床试验申请已获得中国国家药品监督管理局的正式批准。\n这一进展标志着该创新药物将进入临床开发阶段，为后续的疗效与安全性评估铺平了道路。公司致力于推进其生物制药产品管线，此次获批是其研发进程中的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987609","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649987609?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:15","pubTimestamp":1783426507,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于1型糖尿病适应症的临床试验申请获得批准，此前，其用于炎症性肠病适应症的临床试验申请已分别获得国家药品监督管理局批准和FDA许可，用于多发性硬化适应症的临床试验申请已获得国家药品监督管理局批准。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239","BMED","02493","BK1161","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649079984","title":"迈威生物：9MW5211注射液获国家药监局批准开展1型糖尿病临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2649079984","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649079984?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:36","pubTimestamp":1783424169,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648963169","title":"迈威生物（688062）2607万股限售股将于7月3日解禁，占总股本5.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648963169","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648963169?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:02","pubTimestamp":1783036924,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，迈威生物于7月3日将有2607.0万股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本5.84%。本次解禁后，公司还有1.69亿股限售股份，占总股本37.91%。本文数据来源于迈威生物公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300008547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646646809","title":"迈威生物（688062）披露首次公开发行部分限售股上市流通公告，6月25日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646646809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646646809?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:27","pubTimestamp":1782397637,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，迈威生物报收于27.72元，较前一交易日上涨0.14%，最新总市值为123.83亿元。近日，迈威（上海）生物科技股份有限公司发布《首次公开发行部分限售股上市流通公告》。公告显示，公司首次公开发行部分限售股将于2026年7月3日上市流通，本次上市流通数量为26,070,000股，占公司A股股本的6.52%，占总股本的5.84%。上述股东已履行相关承诺，保荐机构对本次限售股上市流通无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239","02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100490246","title":"迈威生物-U获国家药监局批准开展6MW5311注射液临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1100490246","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100490246?lang=zh_cn&edition=full","pubTime":"2026-06-23 23:33","pubTimestamp":1782228835,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司（688062.SS）宣布，其6MW5311注射液的临床试验申请已获得中国国家药品监督管理局的批准。这一进展标志着该候选药物在研发进程中迈出了关键一步，为后续的临床研究铺平了道路。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645880777","title":"迈威生物(688062.SH)：注射用6MW5311临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645880777","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645880777?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:37","pubTimestamp":1782211020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请获得批准。6MW5311是基于公司T Cell Engager(TCE)技术平台开发的一款靶向LILRB4/CD3的双特异性抗体，拟开发适应症为：血液瘤(AML、CMML以及MM)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073615","title":"迈威生物（688062）披露召开2025年度暨2026年第一季度业绩说明会公告，6月22日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645073615?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:31","pubTimestamp":1782138678,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，迈威生物报收于27.08元，较前一交易日下跌1.24%，最新总市值为120.97亿元。该股当日开盘27.01元，最高27.16元，最低25.66元，成交额达2.55亿元，换手率为4.72%。近日，迈威（上海）生物科技股份有限公司发布《关于召开2025年度暨2026年第一季度业绩说明会的公告》。公告显示，公司将于2026年6月30日10:00-11:00通过网络互动方式在“价值在线”平台举办业绩说明会。会议结束后可通过平台查看召开情况及主要内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200038998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644855066","title":"每周股票复盘：迈威生物（688062）9MW2821临床数据亮相ESMO Gynae","url":"https://stock-news.laohu8.com/highlight/detail?id=2644855066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644855066?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:24","pubTimestamp":1781897051,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，迈威生物报收于27.42元，较上周的28.53元下跌3.89%。本周，迈威生物6月15日盘中最高价报28.25元。公司公告汇总：9MW2821在ESMO Gynae以口头报告形式公布宫颈癌临床数据。职工代表大会选举桂勋先生为第三届董事会职工代表董事，其任期自非职工代表董事就任之日起至本届董事会任期届满。迈威生物在2026年欧洲肿瘤内科学会妇科肿瘤年会上以口头报告和壁报形式公布9MW2821治疗复发性或转移性宫颈癌的最新临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000002013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK0239","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143771369","title":"迈威生物宣布胡慧国将卸任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1143771369","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143771369?lang=zh_cn&edition=full","pubTime":"2026-06-19 00:10","pubTimestamp":1781799052,"startTime":"0","endTime":"0","summary":"迈威生物（上海）生物技术股份有限公司宣布，胡慧国将不再担任公司执行董事职务。\n与此同时，公司第三届董事会选举唐春善、刘大涛、吴海、华军为执行董事的决议现已生效。此外，董事会审议并批准了选举刘大涛担任董事长的议案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192147945","title":"迈威生物第三届董事会选举唐春山、刘大涛、吴海、华军为执行董事 决议现已生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1192147945","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192147945?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:43","pubTimestamp":1781790192,"startTime":"0","endTime":"0","summary":"迈威生物第三届董事会选举唐春山、刘大涛、吴海、华军为执行董事的决议现已正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171719233","title":"迈威生物-U（688062）6MW5311临床试验申请获国家药监局受理审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1171719233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171719233?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:32","pubTimestamp":1781263938,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其新药6MW5311的临床试验申请已正式获得国家药品监督管理局的受理，并进入审评阶段。这一进展标志着该候选药物的研发进程向前迈出了关键一步，为后续的临床研究奠定了重要的监管基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186538649","title":"迈威生物-U获美国FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1186538649","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186538649?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:32","pubTimestamp":1781263935,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其已收到美国食品药品监督管理局（FDA）签发的临床试验可以进行通知。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642026565","title":"迈威生物(688062.SH)：注射用6MW5311临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642026565?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:25","pubTimestamp":1781252747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请正式获得FDA许可。此外，6MW5311临床试验申请已获得国家药品监督管理局受理。6MW5311为全球首款获批开展临床试验的靶向LILRB4/CD3的TCE创新药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK4585","688062","02493","BK1161","BK4588","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127863","title":"每周股票复盘：迈威生物（688062）召开两次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127863?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:58","pubTimestamp":1780768691,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，迈威生物报收于26.6元，较上周的30.4元下跌12.5%。本周，迈威生物6月1日盘中最高价报31.44元。本周关注点来自公司公告汇总：迈威生物召开2026年第二次临时股东会，审议通过申请注册发行定向债务融资工具的议案。公司公告汇总迈威（上海）生物科技股份有限公司于2026年6月1日召开2026年第二次临时股东会，会议由董事会召集，董事长刘大涛主持，采用现场与网络投票结合方式召开。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109189720","title":"迈威生物-U 9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1109189720","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109189720?lang=zh_cn&edition=full","pubTime":"2026-06-04 23:43","pubTimestamp":1780587826,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司（股票代码：688062.SS）宣布，其9MW5211注射液的临床试验申请已获得中国国家药品监督管理局（NMPA）的批准。\n这一进展标志着该公司在研产品管线取得了重要一步，为后续的临床开发铺平了道路。市场对此消息反应积极，关注该产品未来的研发进程及其潜在的市场前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122857975","title":"迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1122857975","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122857975?lang=zh_cn&edition=full","pubTime":"2026-06-04 21:12","pubTimestamp":1780578745,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其9MW5211注射液的临床试验申请已获得中国国家药品监督管理局的正式批准。\n公司致力于创新生物药的研发，此次获批标志着其研发管线取得重要进展。9MW5211是一款在研药物，此次获批将推动其进入下一阶段的临床研究，以评估其在目标适应症中的安全性与有效性。\n这一监管进展为公司的长远发展注入了新的动力，也体现了其在生物医药领域的持续创新能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615959","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615959","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640615959?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:05","pubTimestamp":1780567515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于炎症性肠病适应症的临床试验申请获得批准，此外，其用于IBD适应症的美国临床试验申请已获得FDA许可，用于多发性硬化等多个适应症的临床试验申请获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK1161","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640897041","title":"从ASCO数据到迈卫健扩围：迈威生物创新与商业化并进","url":"https://stock-news.laohu8.com/highlight/detail?id=2640897041","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640897041?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:20","pubTimestamp":1780478447,"startTime":"0","endTime":"0","summary":"从ASCO上的亮眼数据，到ESMO GC即将揭晓的宫颈癌数据，再到迈卫健的适应症“扩围”:迈威生物在短时间内打出了一套漂亮的“组合拳”。","market":"hk","thumbnail":"https://img2.gelonghui.com/d273d-c22ea71a-0f20-4fd3-9fb7-a14ae8e7ce94.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-c22ea71a-0f20-4fd3-9fb7-a14ae8e7ce94.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5047096","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0239","02493","BK1161","688062"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783812148880,"stockEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.1687},{"period":"3month","weight":-0.1593},{"period":"6month","weight":-0.3037},{"period":"1year","weight":0.0044},{"period":"ytd","weight":-0.1716}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.0025},{"period":"6month","weight":-0.0302},{"period":"1year","weight":0.1386},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18977人(较上一季度增加2.21%)","perCapita":"12132股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"44673万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物和重组蛋白、小分子化学药等药物。","listedPrice":34.8},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-U(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-U(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-U,688062,迈威生物-U股票,迈威生物-U股票老虎,迈威生物-U股票老虎国际,迈威生物-U行情,迈威生物-U股票行情,迈威生物-U股价,迈威生物-U股市,迈威生物-U股票价格,迈威生物-U股票交易,迈威生物-U股票购买,迈威生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-U(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-U(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}